ÂÜÀòÂÒÂ×

Ziyang Yu is an experienced professional in the field of translational medicine and oncology, currently serving as the Director of Translational Medicine at Parabilis Medicines since April 2022, where Ziyang supports pre-IND to early clinical proof of concept programs. Previously, Ziyang held key leadership roles at Constellation Pharmaceuticals, overseeing the EZH2 Translational Science Team and managing clinical biomarker development, demonstrating expertise in biomarker strategy formulation and data analysis. Ziyang's extensive background includes directorial positions at Radius Health, Inc., where Ziyang led translational research for oncology assets, and early roles in research and public health at esteemed institutions, including Beth Israel Deaconess Medical Center and Zhejiang Provincial Center for Disease Control. Ziyang holds a Ph.D. in Biochemistry and Cell and Molecular Biology from Boston University School of Medicine, complemented by a Master's in Immunology and a Bachelor's in Preventive Medicine from Zhejiang University.